168292-71-5Relevant articles and documents
THERAPEUTIC COMPOUNDS
-
Page/Page column 32, (2017/08/22)
The present invention relates to compounds that are antagonists of the orexin-1 receptor. The compounds have the structural formula (I) defined herein. The present invention also relates to processes for the preparation of these compounds, to pharmaceutical compositions comprising them, and to their use in the treatment of diseases or disorders associated with orexin-1 receptor activity.
L-alanine-derived chiral ligands for asymmetric addition of diethylzinc to aldehydes
Kang, Seock Yong,Baek, Jinho,Kang, Kyoung Hee,Lee, Jeong-Ae,Park, Yong Sun
, p. 3125 - 3128 (2012/10/30)
-
Photoinduced electron transfer (PET) promoted oxidative activation of 1- (N-benzyl-N-methylglycyl)-(S)-prolinol: Development of novel strategies towards enantioselective syntheses of α-amino acids, their N-methyl derivatives and α-hydroxy acids employing
Pandey, Ganash,Das, Parthasarathi,Reddy, P. Yella
, p. 657 - 664 (2007/10/03)
PET activation of 1-(N-benzyl-N-methylglycyl)-(S)-prolinol (1) in dry acetonitrile, utilizing 1,4-dicyanonaphthalene (DCN) as a light-harvesting electron-acceptor and methyl viologen (MV++) as an electron-transfer mediator, leads to the formati